Cargando…
Aging: A cell source limiting factor in tissue engineering
Tissue engineering has yet to reach its ideal goal, i.e. creating profitable off-the-shelf tissues and organs, designing scaffolds and three-dimensional tissue architectures that can maintain the blood supply, proper biomaterial selection, and identifying the most efficient cell source for use in ce...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828594/ https://www.ncbi.nlm.nih.gov/pubmed/31692986 http://dx.doi.org/10.4252/wjsc.v11.i10.787 |
_version_ | 1783465381399101440 |
---|---|
author | Khorraminejad-Shirazi, Mohammadhossein Dorvash, Mohammadreza Estedlal, Alireza Hoveidaei, Amir Human Mazloomrezaei, Mohsen Mosaddeghi, Pouria |
author_facet | Khorraminejad-Shirazi, Mohammadhossein Dorvash, Mohammadreza Estedlal, Alireza Hoveidaei, Amir Human Mazloomrezaei, Mohsen Mosaddeghi, Pouria |
author_sort | Khorraminejad-Shirazi, Mohammadhossein |
collection | PubMed |
description | Tissue engineering has yet to reach its ideal goal, i.e. creating profitable off-the-shelf tissues and organs, designing scaffolds and three-dimensional tissue architectures that can maintain the blood supply, proper biomaterial selection, and identifying the most efficient cell source for use in cell therapy and tissue engineering. These are still the major challenges in this field. Regarding the identification of the most appropriate cell source, aging as a factor that affects both somatic and stem cells and limits their function and applications is a preventable and, at least to some extents, a reversible phenomenon. Here, we reviewed different stem cell types, namely embryonic stem cells, adult stem cells, induced pluripotent stem cells, and genetically modified stem cells, as well as their sources, i.e. autologous, allogeneic, and xenogeneic sources. Afterward, we approached aging by discussing the functional decline of aged stem cells and different intrinsic and extrinsic factors that are involved in stem cell aging including replicative senescence and Hayflick limit, autophagy, epigenetic changes, miRNAs, mTOR and AMPK pathways, and the role of mitochondria in stem cell senescence. Finally, various interventions for rejuvenation and geroprotection of stem cells are discussed. These interventions can be applied in cell therapy and tissue engineering methods to conquer aging as a limiting factor, both in original cell source and in the in vitro proliferated cells. |
format | Online Article Text |
id | pubmed-6828594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-68285942019-11-05 Aging: A cell source limiting factor in tissue engineering Khorraminejad-Shirazi, Mohammadhossein Dorvash, Mohammadreza Estedlal, Alireza Hoveidaei, Amir Human Mazloomrezaei, Mohsen Mosaddeghi, Pouria World J Stem Cells Review Tissue engineering has yet to reach its ideal goal, i.e. creating profitable off-the-shelf tissues and organs, designing scaffolds and three-dimensional tissue architectures that can maintain the blood supply, proper biomaterial selection, and identifying the most efficient cell source for use in cell therapy and tissue engineering. These are still the major challenges in this field. Regarding the identification of the most appropriate cell source, aging as a factor that affects both somatic and stem cells and limits their function and applications is a preventable and, at least to some extents, a reversible phenomenon. Here, we reviewed different stem cell types, namely embryonic stem cells, adult stem cells, induced pluripotent stem cells, and genetically modified stem cells, as well as their sources, i.e. autologous, allogeneic, and xenogeneic sources. Afterward, we approached aging by discussing the functional decline of aged stem cells and different intrinsic and extrinsic factors that are involved in stem cell aging including replicative senescence and Hayflick limit, autophagy, epigenetic changes, miRNAs, mTOR and AMPK pathways, and the role of mitochondria in stem cell senescence. Finally, various interventions for rejuvenation and geroprotection of stem cells are discussed. These interventions can be applied in cell therapy and tissue engineering methods to conquer aging as a limiting factor, both in original cell source and in the in vitro proliferated cells. Baishideng Publishing Group Inc 2019-10-26 2019-10-26 /pmc/articles/PMC6828594/ /pubmed/31692986 http://dx.doi.org/10.4252/wjsc.v11.i10.787 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Review Khorraminejad-Shirazi, Mohammadhossein Dorvash, Mohammadreza Estedlal, Alireza Hoveidaei, Amir Human Mazloomrezaei, Mohsen Mosaddeghi, Pouria Aging: A cell source limiting factor in tissue engineering |
title | Aging: A cell source limiting factor in tissue engineering |
title_full | Aging: A cell source limiting factor in tissue engineering |
title_fullStr | Aging: A cell source limiting factor in tissue engineering |
title_full_unstemmed | Aging: A cell source limiting factor in tissue engineering |
title_short | Aging: A cell source limiting factor in tissue engineering |
title_sort | aging: a cell source limiting factor in tissue engineering |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828594/ https://www.ncbi.nlm.nih.gov/pubmed/31692986 http://dx.doi.org/10.4252/wjsc.v11.i10.787 |
work_keys_str_mv | AT khorraminejadshirazimohammadhossein agingacellsourcelimitingfactorintissueengineering AT dorvashmohammadreza agingacellsourcelimitingfactorintissueengineering AT estedlalalireza agingacellsourcelimitingfactorintissueengineering AT hoveidaeiamirhuman agingacellsourcelimitingfactorintissueengineering AT mazloomrezaeimohsen agingacellsourcelimitingfactorintissueengineering AT mosaddeghipouria agingacellsourcelimitingfactorintissueengineering |